Stay updated on TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial page.

Latest updates to the TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedAdded updated Study Status and Contacts/Locations sections (version 59, published 2026-03-25) and a deletion on 2026-02-17.SummaryDifference0.3%

- Check18 days agoChange DetectedAdded revision v3.5.0 and removed revision v3.4.3 in the Record History.SummaryDifference0.1%

- Check25 days agoChange DetectedA new revision entry v3.4.3 is added to the version history, replacing the previous v3.4.2.SummaryDifference0.1%

- Check46 days agoChange DetectedResults and related sections have been posted (Results, Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, Study Status), and the prior 'Results Submitted' entry has been removed.SummaryDifference0.6%

- Check54 days agoChange DetectedA new Revision: v3.4.2 was added to the history; notices about government funding lapse and the Revision: v3.4.1 entry were removed.SummaryDifference0.4%

- Check61 days agoChange DetectedThe study record history updates to show Results Submitted and Revision: v3.4.1, replacing the previous No Results Posted status; a site-wide government funding notice was also added.SummaryDifference0.5%

Stay in the know with updates to TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial page.